drugset / Trial / NCT04943653
Intraperitoneal Paclitaxel With XELOX in Gastric Cancer With Peritoneal Metastasis
NaSingle-groupOpen-labelTreatment
Summary
IPXELOX will investigate the safety, tolerability, and antitumor activity of intraperitoneal paclitaxel in combination with chemotherapy in patients with advanced gastric cancer with peritoneal metastasis. Study hypotheses: Intraperitoneal paclitaxel administered to subjects at the recommended phase 2 dose will show manageable safety and tolerability and anti-tumor efficacy with systemic capecitabine and oxaliplatin in advanced gastric cancer with peritoneal metastasis.
Timeline
- Start
- 2021-06-08
- Primary completion
- 2023-12
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paclitaxel | Small molecule | 20 mg/m2 | Other |
| Subject | Paclitaxel | Small molecule | 40 mg/m2 | Other |
| Subject | Paclitaxel | Small molecule | 60 mg/m2 | Other |
| Background | Capecitabine | Small molecule | 2000 mg/m2 | — |
| Background | Oxaliplatin | Small molecule | 100 mg/m2 | Intravenous |